1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse events grade 3 or higher occurred in 13.0% with pembrolizumab vs 1.5% with placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Triple-negative breast cancer (TNBC) is an aggressive subtype that lacks key therapeutic targets, leading […]
The post Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer first appeared on Physician’s Weekly.
